43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Opioids for Chronic Noncancer Pain : A Systematic Review and Meta-analysis

      research-article
      , DC, PhD 1 , 2 , 3 , 4 , , , PhD 1 , 2 , 5 , , MB BCh 6 , , MSc 3 , , DC, MSc 3 , 7 , , DDS, MSc 8 , , PhD 3 , 9 , , ScD, MSc 10 , , PhD 11 , , BHSc 12 , , MD 13 , , MD 14 , , MD 15 , , MBBS, DA 1 , 3 , 16 , , MD 17 , , MD 17 , , MD 3 , 18 , , MA, MISt 1 , , MBChB 19 , , MBBS 20 , , MD, PhD 21 , , BA 3 , , MD 22 , , MD 3 , 23 , 24 , , MD 2 , 25 , , PhD 3 , , MD, PhD 1 , 26 , , MD, MSc 1 , 27 , , BMSc 28 , , PhD 3 , , PhD 3 , 29 , , MD, MSc 24 , , PhD 3 , 5 , , MD 1 , 2 , , MD 30 , , MD, MSc 3
      JAMA
      American Medical Association

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Is the use of opioids to treat chronic noncancer pain associated with greater benefits or harms compared with placebo and alternative analgesics?

          Findings

          In this meta-analysis that included 96 randomized clinical trials and 26 169 patients with chronic noncancer pain, the use of opioids compared with placebo was associated with significantly less pain (−0.69 cm on a 10-cm scale) and significantly improved physical functioning (2.04 of 100 points), but the magnitude of the association was small. Opioid use was significantly associated with increased risk of vomiting.

          Meaning

          Opioids may provide benefit for chronic noncancer pain, but the magnitude is likely to be small.

          Abstract

          Importance

          Harms and benefits of opioids for chronic noncancer pain remain unclear.

          Objective

          To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain.

          Data Sources and Study Selection

          The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control.

          Data Extraction and Synthesis

          Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence.

          Main Outcomes and Measures

          The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting.

          Results

          Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], −0.69 cm [95% CI, −0.82 to −0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, −0.60 cm [95% CI, −1.54 to 0.34 cm]; physical functioning: WMD, −0.90 points [95% CI, −2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, −0.13 cm [95% CI, −0.99 to 0.74 cm]; physical functioning: WMD, −5.31 points [95% CI, −13.77 to 3.14 points]), and anticonvulsants (pain: WMD, −0.90 cm [95% CI, −1.65 to −0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, −5.77 to 6.66 points]).

          Conclusions and Relevance

          In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.

          Abstract

          This systematic review and meta-analysis of randomized clinical trials comparing opioid vs nonopioid treatment of chronic noncancer pain estimates the association of opioids with pain intensity, physical function, and incidence of vomiting.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis.

          Opioid use in chronic pain treatment is complex, as patients may derive both benefit and harm. Identification of individuals currently using opioids in a problematic way is important given the substantial recent increases in prescription rates and consequent increases in morbidity and mortality. The present review provides updated and expanded information regarding rates of problematic opioid use in chronic pain. Because previous reviews have indicated substantial variability in this literature, several steps were taken to enhance precision and utility. First, problematic use was coded using explicitly defined terms, referring to different patterns of use (ie, misuse, abuse, and addiction). Second, average prevalence rates were calculated and weighted by sample size and study quality. Third, the influence of differences in study methodology was examined. In total, data from 38 studies were included. Rates of problematic use were quite broad, ranging from <1% to 81% across studies. Across most calculations, rates of misuse averaged between 21% and 29% (range, 95% confidence interval [CI]: 13%-38%). Rates of addiction averaged between 8% and 12% (range, 95% CI: 3%-17%). Abuse was reported in only a single study. Only 1 difference emerged when study methods were examined, where rates of addiction were lower in studies that identified prevalence assessment as a primary, rather than secondary, objective. Although significant variability remains in this literature, this review provides guidance regarding possible average rates of opioid misuse and addiction and also highlights areas in need of further clarification.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Guideline for opioid therapy and chronic noncancer pain.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

              I focus on issues surrounding the promotion and marketing of controlled drugs and their regulatory oversight. Compared with noncontrolled drugs, controlled drugs, with their potential for abuse and diversion, pose different public health risks when they are overpromoted and highly prescribed. An in-depth analysis of the promotion and marketing of OxyContin illustrates some of the associated issues. Modifications of the promotion and marketing of controlled drugs by the pharmaceutical industry and an enhanced capacity of the Food and Drug Administration to regulate and monitor such promotion can have a positive impact on the public health.
                Bookmark

                Author and article information

                Journal
                JAMA
                JAMA
                JAMA
                JAMA
                American Medical Association
                0098-7484
                1538-3598
                18 December 2018
                18 December 2018
                18 June 2019
                : 320
                : 23
                : 2448-2460
                Affiliations
                [1 ]Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada
                [2 ]Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
                [3 ]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
                [4 ]Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University, Hamilton, Ontario, Canada
                [5 ]Chinese Cochrane Centre, West China Hospital, Sichuan University, Chengdu
                [6 ]Faculty of Medicine, Ain Shams University, Cairo, Egypt
                [7 ]Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
                [8 ]Krembil Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada
                [9 ]Now with the Canadian Agency for Drugs and Technologies in Health (CADTH), Toronto, Ontario, Canada
                [10 ]Pharmaceutical Science, University of Sorocaba, Sao Paulo, Brazil
                [11 ]Leonardo Hirslanden Klinik Birshof, Münchenstein, Switzerland
                [12 ]Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
                [13 ]Department of Internal Medicine, Hospital Alemán de Buenos Aires, Buenos Aires, Argentina
                [14 ]Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, Ontario, Canada
                [15 ]Department of Anesthesiology, Perioperative and Pain Medicine, University of Calgary, Calgary, Alberta, Canada
                [16 ]Department of Family Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada
                [17 ]Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
                [18 ]Department of Medicine, University of Toronto, Toronto, Ontario, Canada
                [19 ]Accident and Emergency Department, Queen Mary Hospital, Pokfulam, Hong Kong, China
                [20 ]Accident and Emergency Department, Tuen Mun Hospital, Hong Kong, China
                [21 ]Department of Medicine, Gjøvik, Innlandet Hospital Trust, Norway
                [22 ]Department of Hygiene and Dietetics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
                [23 ]Institute for Clinical Epidemiology and Biostatistics, University of Basel Hospital, Basel, Switzerland
                [24 ]Department of Clinical Research, University of Basel Hospital, Basel, Switzerland.
                [25 ]Department of Anesthesiology, Operative Intensive Care, Preclinical Emergency Medicine and Pain Management, University of Basel Hospital, Basel, Switzerland
                [26 ]Isfahan Medical Education Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
                [27 ]Canadian Academy of Osteopathy, Hamilton, Ontario, Canada
                [28 ]Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
                [29 ]Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
                [30 ]Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio
                Author notes
                Article Information
                Corresponding Author: Jason W. Busse, DC, PhD, Department of Anesthesia, Michael G. DeGroote School of Medicine, McMaster University, HSC-2V9, 1280 Main St W, Hamilton, ON L8S 4K1, Canada ( bussejw@ 123456mcmaster.ca ).
                Accepted for Publication: October 30, 2018.
                Author Contributions: Drs Busse and Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Busse, Schandelmaier, Johnston, Buckley, Sessler, Guyatt.
                Acquisition, analysis, or interpretation of data: Busse, Wang, Kamaleldin, Craigie, Riva, Montoya, Mulla, Lopes, Vogel, Chen, Kirmayr, De Oliveira, Olivieri, Kaushal, Chaparro, Oyberman, Agarwal, Couban, Tsoi, Lam, Vandvik, Hsu, Bala, Schandelmaier, Scheidecker, Ebrahim, Ashoorion, Rehman, Hong, Sun, Buckley, Guyatt.
                Drafting of the manuscript: Busse, Craigie, Kirmayr, Oyberman, Ebrahim, Johnston.
                Critical revision of the manuscript for important intellectual content: Busse, Wang, Kamaleldin, Craigie, Riva, Montoya, Mulla, Lopes, Vogel, Chen, De Oliveira, Olivieri, Kaushal, Chaparro, Agarwal, Couban, Tsoi, Lam, Vandvik, Hsu, Bala, Schandelmaier, Scheidecker, Ebrahim, Ashoorion, Rehman, Hong, Sun, Buckley, Sessler, Guyatt.
                Statistical analysis: Wang.
                Obtained funding: Busse, Johnston, Buckley.
                Administrative, technical, or material support: Kamaleldin, Craigie, Riva, Lopes, Vogel, Kirmayr, De Oliveira, Olivieri, Kaushal, Chaparro, Oyberman, Agarwal, Couban, Lam, Vandvik, Hsu, Ebrahim, Rehman, Hong.
                Supervision: Busse, Craigie, Vandvik, Buckley.
                Conflict of Interest Disclosures: Dr Buckley reported receiving personal fees from Purdue Pharma and Nova Scotia College of Physicians and Surgeons. No other disclosures were reported.
                Funding/Support: This study was supported by grant 119801 from the Canadian Institutes of Health Research and grant 1516-HQ-000017 from Health Canada. Dr Riva is supported by a PhD training award from the NCMIC Foundation.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: We thank Wichor Bramer, BSc (Erasmus University Medical Center), Brian Alper, MD, MSPH, FAAFP (DynaMed Plus, EBSCO Health), and Neera Bhatnagar, BSc, MLiS (McMaster University Health Sciences Library), for peer review of the MEDLINE search strategy. We thank Yaping Chang, PhD (Department of Health Research Methods, Evidence, and Impact, McMaster University), Yvgeniy Oparin, BHSc (Michael G. DeGroote School of Medicine, McMaster University), Kayli Culig, BHSc (Faculty of Medicine, University of Toronto), Raad Yameen, MD (Institute of Medical Sciences, University of Toronto and Department of Family Medicine, University of Manitoba), Curtis May, BKin (Faculty of Medicine, University of British Columbia), Anna Goshua, BHSc (Faculty of Health Sciences, McMaster University), Annie Lok, HBA, MHE (Faculty of Health Sciences, McMaster University), and Regina Li, HBA, MSc (Faculty of Health Sciences, McMaster University) for screening citations. We thank Norman Buckley, MD (Department of Anesthesia, McMaster University), Dwight Moulin, MD (Department of Clinical Neurological Sciences, Western University), David Juurlink, MD, PhD (Departments of Medicine and Pediatrics, University of Toronto), Sol Stern, MD (Argus Medical Centre, Oakville), and Lydia Hatcher, MD (Department of Family Medicine, St Joseph’s Healthcare Hamilton), for review and feedback regarding the morphine equianalgesic table. We thank Linn Brandt, MD (Department of Internal Medicine, Gjøvik Sykehus, Sykehuset Innlandet Hospital Trust), Jan Brozek, MD, PhD (Department of Health Research Methods, Evidence, and Impact, McMaster University), Eva Dobos, MD (Szeged University of Medicine), Toshiaki A. Furukawa, MD, PhD (Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health), Andrea Rita Horvath, MD, PhD (Department of Clinical Chemistry and Endocrinology, New South Wales Health Pathology), Roman Jaeschke, MD, MSc (Department of Medicine, McMaster University), Annette Kristiansen, MD (Department of Health and Science, University of Oslo), Frances LeBlanc, DC (New Brunswick Chiropractic Association), Giovanna Lurati Buse, MD, MSc (Basel University Hospital), Irene Marzona, Pharmacy DR, MSc (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri), Marek Nemec, MD (Department of Emergency Medicine, Basel University Hospital), Josef Prazak MD, PhD (Bern University Hospital), Dmitry Shiktorov, MD (Canadian Centre for Clinical Trials), Aran Tajika, MD (Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health), Brian Younho Hong, BHSc (Department of Medicine, University of Ottawa), and Konstantin Tikhonov, MD (University Health Network, Toronto), for screening the full texts of non-English articles. No financial compensation was provided to any of these individuals.
                Article
                PMC6583638 PMC6583638 6583638 joi180142
                10.1001/jama.2018.18472
                6583638
                30561481
                96d19f6f-8bd2-4ae5-b21e-82fc24e0dea7
                Copyright 2018 American Medical Association. All Rights Reserved.
                History
                : 11 October 2017
                : 25 October 2018
                : 30 October 2018
                Funding
                Funded by: Canadian Institutes of Health Research
                Funded by: Health Canada
                Funded by: NCMIC Foundation
                Categories
                Research
                Research
                Original Investigation

                Comments

                Comment on this article